Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
36 studies found for:    targeted therapy HER2-positive | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Cardiac Safety Study in Patients With HER2 + Breast Cancer
Conditions: HER2 Positive Breast Cancer;   Left Ventricular Function Systolic Dysfunction
Intervention: Drug: Trastuzumab, Pertuzumab, Ado-trastuzumab emtansine
2 Recruiting Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer
Condition: Gastric Cancer
Intervention: Other: CTC and cfDNA analysis
3 Recruiting Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Conditions: Breast Cancer;   Gastric Cancer;   Solid Tumors;   NSCLC
Intervention: Drug: Pyrotinib
4 Recruiting Detect V / CHEVENDO (Chemo vs. Endo)
Condition: Metastatic Breast Cancer
Interventions: Drug: pertuzumab;   Drug: Trastuzumab;   Drug: Capecitabine;   Drug: Paclitaxel;   Drug: Vinorelbine;   Drug: Docetaxel;   Drug: Exemestane;   Drug: Letrozole;   Drug: Anastrozole;   Drug: Fulvestrant;   Drug: Tamoxifen
5 Not yet recruiting Adapted Physical Activity for Breast Cancer HER2 Positive Patient
Condition: HER2 Positive Breast Cancer
Intervention: Other: Home-based Adapted Physical Activity
6 Not yet recruiting Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
Conditions: HER-2 Positive Breast Cancer;   Estrogen Receptor Positive Breast Cancer
Interventions: Drug: palbociclib;   Drug: trastuzumab;   Drug: pertuzumab;   Drug: letrozole;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant
7 Recruiting DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
Conditions: HER2-negative Metastatic Breast Cancer;   HER2-positive Circulating Tumor Cells
Interventions: Drug: standard chemo- or endocrine therapy;   Drug: standard chemo- or endocrine therapy + Lapatinib
8 Recruiting Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib;   Biological: Trastuzumab
9 Not yet recruiting Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Tucatinib in Combination with Palbociclib and Letrozole
10 Recruiting Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Conditions: HER2/Neu Positive;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu Intracellular Domain Protein;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Placebo;   Biological: Polysaccharide-K;   Biological: Trastuzumab
11 Recruiting A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Conditions: Breast Cancer;   Ovarian Cancer;   Lung Cancer;   Gastric Cancer;   Colorectal Cancer;   Glioma;   Pancreatic Cancer
Intervention: Biological: Anti-HER2 CAR-T
12 Recruiting Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients
Condition: Breast Cancer Nos Premenopausal
Interventions: Drug: Docetaxel;   Drug: epirubicin;   Drug: cyclophosphamide;   Procedure: Modified radical mastectomy or breast-conserving Surgery;   Drug: Docetaxel (post-operative);   Drug: Epirubicin (post-operative);   Drug: Cyclophosphamide (post-operative);   Radiation: Radiation therapy;   Drug: Herceptin (post-operative);   Drug: Tamoxifen (post-operative)
13 Not yet recruiting BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Condition: Breast Cancer
Interventions: Drug: paclitaxel;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Carboplatin;   Procedure: Breast surgery;   Drug: AC
14 Recruiting Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Conditions: Esophageal Cancer;   Gastric Cancer
Intervention: Drug: Afatinib and Paclitaxel
15 Recruiting A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Neratinib;   Drug: T-DM1
16 Recruiting Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
Conditions: HER2 Positive Breast Carcinoma;   Invasive Breast Carcinoma;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Radiation: Stereotactic Radiosurgery;   Radiation: Whole-Brain Radiotherapy
17 Recruiting Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: MK-3475
18 Recruiting Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Letrozole
19 Recruiting Exosomal and Free Extracellular RNAs and Proteins as Predictive. ICORG 10-15, V2
Conditions: Breast Cancer;   HER2 Positive Breast Cancer;   HER2 Negative Breast Cancer
Intervention: Other: Biomarker Analysis
20 Recruiting Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Paclitaxel + Carboplatin + ASLAN001

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.